#Israel #Omer #Pulsenmore Ltd #maternal-fetal healthcare #remote ultrasound

Pulsenmore Ltd. Reveals Business Advances and Financial Results for H1 2026

Pulsenmore Ltd., traded on NASDAQ under the ticker PLSM, has recently shared significant financial updates and operational highlights from the first half of 2026. The company stands out as a leader in the field of remote maternal-fetal healthcare, focusing on innovative home ultrasound solutions. As it navigated through this transformative period, Pulsenmore solidified its position by advancing commercialization efforts, securing vital partnerships, and achieving notable regulatory milestones.

Highlights from H1 2026

Commercial Developments

During the initial six months of 2026, Pulsenmore successfully launched its U.S. commercial operations following the receipt of FDA marketing authorization for its groundbreaking home ultrasound platform. The platform was introduced at the Society for Maternal-Fetal Medicine (SMFM) Pregnancy Meeting in Las Vegas in February, showcasing the company's commitment to revolutionizing pregnancy monitoring.

The company's efforts resulted in significant agreements with key players in the maternal-fetal healthcare arena, including:

• - The Center for Fetal Maternal Ultrasound in Los Angeles, California
• - TLC Perinatal Care in Silver Spring, Maryland

Moreover, Pulsenmore celebrated its first U.S. ultrasound patient scan in February and officially opened its e-commerce portal for online orders in April 2026. The expansion of discussions with digital health organizations further underscores the company's dedication to increasing accessibility to virtual obstetric care across diverse communities.

In a pivotal move, Pulsenmore entered into a strategic partnership with Ouma Health in June 2026, aiming to enhance access to remote prenatal care for underserved populations. This collaboration seeks to provide critical insights that will aid future expansions with healthcare systems and maternity care providers.

Innovations and Regulatory Progress

In the realm of product development, Pulsenmore made strides by submitting documentation to the FDA and AMAR for its ES Tera product line, which is compatible with both iOS and Android devices. The company received necessary regulatory clearances, reflecting its commitment to innovation and development.

The initial production lots of the ES Tera products were completed and prepared for shipment to the U.S. market, indicating a robust pipeline for future sales. Additionally, in July 2026, Pulsenmore was selected for participation in Israel's Healthcare AI Regulatory Sandbox Program. This grant approval translates to significant funding aimed at promoting technological innovations through AI integration in healthcare.

Manufacturing and Intellectual Property

During the first half of 2026, Pulsenmore sold approximately 4,265 devices and continued to expand its production capabilities. The planning for new manufacturing facilities highlights the company's aspiration for growth and efficiency. Meanwhile, the strengthening of its intellectual property portfolio with several new patents serves to protect its innovations and enhances its competitive edge in the market.

Financial Overview

Pulsenmore reported impressive financial results for the six months ending June 30, 2026. The company achieved revenues amounting to NIS 6.1 million, a notable increase from previous periods, largely driven by enhanced sales of the Pulsenmore ES units. The shift in revenue streams from diversified customer bases marks a pivotal point for the company's growth trajectory.

However, the financial landscape was not without challenges. Operating expenses rose to NIS 23 million, reflecting the company's efforts towards commercialization and product development. Despite an increase in operating loss, management remains optimistic, equating these investments with future revenue potential, especially as the company scales its operations and converts growth initiatives into actual sales.

Dr. Elazar Sonnenschein, CEO of Pulsenmore, emphasized the significance of these results, noting that they reflect a transformative phase for the company in terms of growth, revenue generation, and expansion into new markets. As they move forward into the latter half of 2026, Pulsenmore's focus remains on building its commercial base and enhancing the accessibility of remote maternal-fetal healthcare globally.

Conclusion

Pulsenmore Ltd. is poised for a promising future in the healthcare industry, marked by significant developments in technology and regulatory approvals. As it builds on its recent achievements, the company stands at the forefront of revolutionizing how maternal-fetal care is delivered, making it more accessible and efficient for future generations. For more detailed information, visit their Investor Relations site.